Rare Genetic Variants Associated with Sudden Cardiac Death
|
By LabMedica International staff writers Posted on 04 Dec 2019 |

Image: Gene Sequencing identifies pathogenic variants in sudden cardiac death versus controls and asymptomatic adults (Photo courtesy of Massachusetts General Hospital)
A recent study has assessed the prevalence of rare pathogenic variants in sudden cardiac death cases versus controls, and the prevalence and clinical importance of such mutations in an asymptomatic adult population.
Sudden cardiac death occurs in around 220,000 adults in the USA annually, the majority of whom have no prior symptoms or cardiovascular diagnosis. Rare pathogenic DNA variants in any of 49 genes can pre-dispose to four important causes of sudden cardiac death: cardiomyopathy, coronary artery disease, inherited arrhythmia syndrome, and aortopathy or aortic dissection.
A large team of scientists working with the Massachusetts General Hospital (Boston, MA, USA) performed whole-exome sequencing in a case-control cohort of 600 adult-onset sudden cardiac death cases and 600 matched controls from 106,098 participants of six prospective cohort studies. Observed DNA sequence variants in any of 49 genes with known association to cardiovascular disease were classified as pathogenic or likely pathogenic by a clinical laboratory geneticist blinded to case status. In an independent population of 4,525 asymptomatic adult participants of a prospective cohort study, the team performed whole-genome sequencing and determined the prevalence of pathogenic or likely pathogenic variants and prospective association with cardiovascular death.
The scientists reported that among the 1,200 sudden cardiac death cases and controls, they identified 5,178 genetic variants and classified 14 as pathogenic or likely pathogenic. These 14 variants were present in 15 individuals, all of whom had experienced sudden cardiac death, corresponding to a pathogenic variant prevalence of 2.5% in cases and 0% in controls. Among the 4,525 participants of the prospective cohort study, 41 (0.9%) carried a pathogenic or likely pathogenic variant and these individuals had 3.24-fold higher risk of cardiovascular death over a median follow-up of 14.3 years.
Amit V. Khera, MD, MSc, an associate director of the Precision Medicine Unit, said, “This really lays the groundwork to say these are important mutations, and what's exciting is if we can identify them, we have treatments for the conditions to which they are tied. We know each of these diseases tends to run in families and there are genetic variants that cause each of these conditions”.
The authors concluded that gene sequencing identifies a pathogenic or likely pathogenic variant in a small but potentially important subset of adults experiencing sudden cardiac death; these variants are present in ∼1% of asymptomatic adults. The study was published on November 18, 2019 in the Journal of the American College of Cardiology.
Related Links:
Massachusetts General Hospital
Sudden cardiac death occurs in around 220,000 adults in the USA annually, the majority of whom have no prior symptoms or cardiovascular diagnosis. Rare pathogenic DNA variants in any of 49 genes can pre-dispose to four important causes of sudden cardiac death: cardiomyopathy, coronary artery disease, inherited arrhythmia syndrome, and aortopathy or aortic dissection.
A large team of scientists working with the Massachusetts General Hospital (Boston, MA, USA) performed whole-exome sequencing in a case-control cohort of 600 adult-onset sudden cardiac death cases and 600 matched controls from 106,098 participants of six prospective cohort studies. Observed DNA sequence variants in any of 49 genes with known association to cardiovascular disease were classified as pathogenic or likely pathogenic by a clinical laboratory geneticist blinded to case status. In an independent population of 4,525 asymptomatic adult participants of a prospective cohort study, the team performed whole-genome sequencing and determined the prevalence of pathogenic or likely pathogenic variants and prospective association with cardiovascular death.
The scientists reported that among the 1,200 sudden cardiac death cases and controls, they identified 5,178 genetic variants and classified 14 as pathogenic or likely pathogenic. These 14 variants were present in 15 individuals, all of whom had experienced sudden cardiac death, corresponding to a pathogenic variant prevalence of 2.5% in cases and 0% in controls. Among the 4,525 participants of the prospective cohort study, 41 (0.9%) carried a pathogenic or likely pathogenic variant and these individuals had 3.24-fold higher risk of cardiovascular death over a median follow-up of 14.3 years.
Amit V. Khera, MD, MSc, an associate director of the Precision Medicine Unit, said, “This really lays the groundwork to say these are important mutations, and what's exciting is if we can identify them, we have treatments for the conditions to which they are tied. We know each of these diseases tends to run in families and there are genetic variants that cause each of these conditions”.
The authors concluded that gene sequencing identifies a pathogenic or likely pathogenic variant in a small but potentially important subset of adults experiencing sudden cardiac death; these variants are present in ∼1% of asymptomatic adults. The study was published on November 18, 2019 in the Journal of the American College of Cardiology.
Related Links:
Massachusetts General Hospital
Latest Molecular Diagnostics News
- Novel Algorithm Improves Detection of B-ALL Gene Fusions
- Rapid Multiplex PCR Test Detects 11 Gastrointestinal Pathogens from Single Sample
- Sensitive Protein Marker Aids Diagnosis of Small Cell Prostate Cancer
- Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC
- Realistic Mock Samples Aim to Speed Cervical Cancer Test Development
- Blood-Based “Ageing Clock” Helps Predict Dementia Risk and Earlier Onset
- Molecular Marker Identifies Hormone Therapy Resistance Pathway in Prostate Cancer
- Blood Test Refines Biopsy Decisions in Prostate Cancer
- Digital Aging Twin Quantifies Biological Aging Across Multiple Organ Systems
- Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk
- Urine Test Beats MRI in Identifying Prostate Cancer Upgrading During Active Surveillance
- Finger-Prick Blood Test Aids Early Tuberculosis Detection and Risk Stratification
- Patented Isothermal Amplification Chemistry Advances Decentralized Testing
- Direct-to-Patient Genetic Testing Identifies Hereditary Cancer Risk in Survivors
- Stool DNA Analysis Tracks Disease Activity in IBD
- Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Channels
Clinical Chemistry
view channel
Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more
Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read moreMolecular Diagnostics
view channel
Sensitive Protein Marker Aids Diagnosis of Small Cell Prostate Cancer
Accurate identification of aggressive prostate cancer subtypes can be difficult when tumors lose expression of lineage markers used in routine pathology. Small cell carcinoma of the prostate, in particular,... Read more
Rapid Multiplex PCR Test Detects 11 Gastrointestinal Pathogens from Single Sample
Cepheid’s Xpert GI Panel has received CE marking under the In Vitro Diagnostic Medical Devices Regulation (IVDR) and is expected to begin shipping to countries that accept the CE mark in the coming weeks.... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read moreMicrobiology
view channel
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read moreTechnology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read moreIndustry
view channel
AI-Powered Multi-Functional Analyzer Wins German Innovation Award
Hematology services are increasingly delivered across distributed care settings, where limited staffing and complex workflows can extend turnaround times. Advanced morphology review still often depends... Read more








